Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus coagulans + clostridium butyricum
- Development stage
- Unknown
- Lead developer
- Qingdao East Sea Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus coagulans + Clostridium butyricum is a probiotic combination therapy consisting of live spore-forming bacteria. Developed and manufactured by companies such as Qingdao East Sea Pharmaceutical, this combination is primarily used to modulate the gut microbiota and restore intestinal homeostasis. It has been extensively investigated as an adjunct to standard antibiotic-based treatments for the eradication of *Helicobacter pylori* infection, where it helps improve eradication rates and reduce antibiotic-associated side effects like diarrhea. The spores of *B. coagulans* and *C. butyricum* are resistant to gastric acid, allowing them to reach the intestines where they germinate and produce beneficial metabolites, including lactic acid and butyric acid, which inhibit pathogenic bacteria and support mucosal health. The combination has also been studied for its potential role in treating COVID-19-related gastrointestinal symptoms and preclinical models of depression.
- Brand names
- Chang Le KangChanglekang
- Other names
- Bacillus coagulans and Clostridium butyricumB. coagulans + C. butyricumbacillus coagulans + clostridium butylicum
Beyond the preview
Go deeper on bacillus coagulans + clostridium butyricum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus coagulans + clostridium butyricum.